Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Armand

Showing results (81-90 of 205) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humansJ Robert, J P Armand, S Huet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1996
Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studiesJ P Armand, Y M Extra, G Catimel, et al.
Anti-Cancer Drugs|January 12, 2000
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignanciesJ P Armand, D Cunningham, E van Cutsem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patientsD Abigerges, G G Chabot, J P Armand, et al.
Journal De Radiologie|August 1, 1995
[Diagnosis of extrapontine myelinolysis preceding central pontine myelinolysis]J P Armand, V Dousset, S Winnock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trialsL P Rivory, M C Haaz, P Canal, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 1, 1987
Oxidative biotransformation of the antitumour agent elliptinium acetate: Structural characterization of its human and rat urinary metabolitesB Monsarrat, M Maftouh, G Meunier, et al.
Head & Neck|January 1, 1997
Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma typeA Fandi, A Taamma, N Azli, et al.
Head & Neck|May 1, 1993
Correlation between nodal density in contrasted scans and response to cisplatin-based chemotherapy in head and neck squamous cell cancer: a prospective validationF Janot, E Cvitkovic, J D Piekarski, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinizationM de Forni, G G Chabot, J P Armand, et al.
Pageof 21

Showing results (81-90 of 205) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humansJ Robert, J P Armand, S Huet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1996
Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studiesJ P Armand, Y M Extra, G Catimel, et al.
Anti-Cancer Drugs|January 12, 2000
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignanciesJ P Armand, D Cunningham, E van Cutsem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patientsD Abigerges, G G Chabot, J P Armand, et al.
Journal De Radiologie|August 1, 1995
[Diagnosis of extrapontine myelinolysis preceding central pontine myelinolysis]J P Armand, V Dousset, S Winnock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trialsL P Rivory, M C Haaz, P Canal, et al.
Journal of Pharmaceutical and Biomedical Analysis|January 1, 1987
Oxidative biotransformation of the antitumour agent elliptinium acetate: Structural characterization of its human and rat urinary metabolitesB Monsarrat, M Maftouh, G Meunier, et al.
Head & Neck|January 1, 1997
Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma typeA Fandi, A Taamma, N Azli, et al.
Head & Neck|May 1, 1993
Correlation between nodal density in contrasted scans and response to cisplatin-based chemotherapy in head and neck squamous cell cancer: a prospective validationF Janot, E Cvitkovic, J D Piekarski, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinizationM de Forni, G G Chabot, J P Armand, et al.
Pageof 21